Search Results - "Bottini, A."

Isolation, identification and selection of antagonistic yeast against Alternaria alternata infection and tenuazonic acid production in wine grapes from Argentina by Prendes, Luciana P., Merín, María G., Fontana, Ariel R., Bottini, Rubén A., Ramirez, María L., Morata de Ambrosini, Vilma I.

“…Epiphytic isolates with yeast characteristics from grapes of the Malbec cultivar were obtained in order to find antagonists against Alternaria alternata. From…”
Get full text

Neo-adjuvant chemotherapy in luminal, node positive breast cancer: characteristics, treatment, and oncological outcomes. A single center’s experience by Barbieri, E., Gentile, D., Bottini, A., Gatzemeier, W., Sagona, A., Casiraghi, M., Tinterri, C.

Get full text

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment by Ianza, A, Giudici, F, Pinello, C, Corona, SP, Strina, C, Bernocchi, O, Bortul, M, Milani, M, Sirico, M, Allevi, G, Aguggini, S, Cocconi, A, Azzini, C, Dester, M, Cervoni, V, Bottini, A, Cappelletti, M, Generali, D

“…A key tool for monitoring breast cancer patients under neoadjuvant treatment is the identification of reliable predictive markers. Ki67 has been identified as…”
Get full text

The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines by Fragni, M., Bonini, S. A., Bettinsoli, P., Bodei, S., Generali, D., Bottini, A., Spano, P. F., Memo, M., Sigala, S.

“…Preclinical data indicate a direct anti-tumor effect of zoledronic acid (ZA) outside the skeleton, but its molecular mechanism is still not completely…”
Get full text

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer by Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D

“…Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain…”
Get full text

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer by Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D

“…Purpose: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast…”
Get full text

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment by Generali, D, Buffa, F M, Deb, S, Cummings, M, Reid, L E, Taylor, M, Andreis, D, Allevi, G, Ferrero, G, Byrne, D, Martinotti, M, Bottini, A, Harris, A L, Lakhani, S R, Fox, S B

“…Background: Stratification of patients for treatment of ductal carcinoma in situ (DCIS) is suboptimal, with high systemic overtreatment rates. Methods: A…”
Get full text

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature by Boutros, A., Bottini, A., Rossi, G., Tanda, E.T., Spagnolo, F., Barletta, G., Croce, E., Fava, P., Parisi, A., De Rosa, F., Palla, M., Marconcini, R., Ferrari, M., Grandis, M., Spallarossa, P., Sarocchi, M., Arboscello, E., Del Mastro, L., Lambertini, M., Pronzato, P., Genova, C.

“…Immune checkpoint inhibitors (ICIs) have revolutionized the management of multiple tumors, due to improved efficacy, quality of life, and safety. While most…”
Get full text

Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy by Koukourakis, M I, Giatromanolaki, A, Bottini, A, Cappelletti, M R, Zanotti, L, Allevi, G, Strina, C, Ardine, M, Milani, M, Brugnoli, G, Martinotti, M, Ferrero, G, Bertoni, R, Ferrozzi, F, Harris, A L, Generali, D

“…Background: Although Trastuzumab has improved survival of HER2+ breast cancer patients, resistance to the agent pre-exists or develops through the course of…”
Get full text

Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? by Ardine, M., Generali, D., Donadio, M., Bonardi, S., Scoletta, M., Vandone, A. M., Mozzati, M., Bertetto, O., Bottini, A., Dogliotti, L., Berruti, A.

Get full text

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer by Andreis, D, Bonardi, S, Allevi, G, Aguggini, S, Gussago, F, Milani, M, Strina, C, Spada, D, Ferrero, G, Ungari, M, Rocca, A, Nanni, O, Roviello, G, Berruti, A, Harris, A.L, Fox, S.B, Roviello, F, Polom, K, Bottini, A, Generali, D

“…Abstract Background Histological status of axillary lymph nodes is an important prognostic factor in patients receiving surgery for breast cancer (BC)…”
Get full text

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer by Schneeweiss, A., Marmé, F., Ruiz, A., Manikhas, A.G., Bottini, A., Wolf, M., Sinn, H.-P., Mansouri, K., Kennedy, L., Bauknecht, T.

“…Neoadjuvant systemic therapy (NST) before surgery is a standard option for patients with early breast cancer (EBC) that allows in vivo chemosensitivity…”
Get full text

Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1  and Relation to Clinical Response by Generali, D., Berruti, A., Cappelletti, M. R., Zanotti, L., Brugnoli, G., Forti, M., Bedussi, F., Vailati, M. E., Milani, M., Strina, C., Ardine, M., Aguggini, S., Allevi, G., Ferrero, G., Bertoni, R., Bottini, A., Harris, A. L., Fox, S. B.

Get full text

Intermediate Endpoints of Primary Systemic Therapy in Breast Cancer Patients by Berruti, Alfredo, Generali, Daniele, Bertaglia, Valentina, Brizzi, Maria Pia, Mele, Teresa, Dogliotti, Luigi, Bruzzi, Paolo, Bottini, Alberto

“…Primary systemic therapy (PST) in breast cancer offers the opportunity to explore interactions between tumor biology and administered treatment. Changes in…”
Get full text

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer by BOTTINI, A, BERRUTI, A, BETRI, E, BERTOLI, G, ALQUATI, P, DOGLIOTTI, L, BERSIGA, A, BRIZZI, M. P, BRUZZI, P, AGUGGINI, S, BRUNELLI, A, BOLSI, G, ALLEVI, G, GENERALI, D

“…The association between tumour shrinkage and reduction in kinetic cell activity after primary chemotherapy in human breast cancer is still a matter of…”
Get full text

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis by Dovio, A., Generali, D., Tampellini, M., Berruti, A., Tedoldi, S., Torta, M., Bonardi, S., Tucci, M., Allevi, G., Aguggini, S., Bottini, A., Dogliotti, L., Angeli, A.

“…Summary The variability of serum osteoprotegerin (OPG) and soluble RANKL (sRANKL) along the 24-h cycle was assessed in 20 healthy women. No rhythmic variations…”
Get full text

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases by Generali, D, Dovio, A, Tampellini, M, Tucci, M, Tedoldi, S, Torta, M, Bonardi, S, Allevi, G, Aguggini, S, Milani, M, Harris, A L, Bottini, A, Dogliotti, L, Angeli, A, Berruti, A

“…Persistent circadian rhythm of bone turnover in bone metastatic breast cancer suggests greater skeletal retention of bisphosphonates if administered in the…”
Get full text

Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial by Bottini, A, Berruti, A, Brizzi, M P, Bersiga, A, Generali, D, Allevi, G, Aguggini, S, Bolsi, G, Bonardi, S, Tondelli, B, Vana, F, Tampellini, M, Alquati, P, Dogliotti, L

“…This study was designed to address whether simultaneous primary chemo-hormonal therapy provides additional activity compared with chemotherapy alone in breast…”
Get full text

Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study by Sapino, A., Montemurro, F., Marchiò, C., Viale, G., Kulka, J., Donadio, M., Bottini, A., Botti, G., dei Tos, A.P., Bersiga, A., Di Palma, S., Truini, M., Sanna, G., Aglietta, M., Bussolati, G.

“…Biotin-labeled trastuzumab (BiotHER) can be used to test for HER2 by immunohistochemistry. We previously showed that BiotHER immunoreactivity is highly…”
Get full text

Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer by BOTTINI, A, BERRUTI, A, ALQUATI, P, DOGLIOTTI, L, BRIZZI, M. P, BERSIGA, A, GENERALI, D, ALLEVI, G, AGUGGINI, S, BOLSI, G, BONARDI, S, BERTOLI, G

“…The purpose of this study was to evaluate whether tumour response to primary chemotherapy in human breast cancer is influenced by baseline haemoglobin (Hb)…”
Get full text